2023 VISION Registry Data Report

I. The Patient Journey

Did the patient have a biopsy?

Out of the 62% of patients who had a biopsy, in retrospect, how likely were they to make the same decision?

62%

38%

12%

Not at all

Yes

No

2%

A little bit

9%

Somewhat

How did the biopsy results affect the patient’s treatment and care? Check all that apply.

Why did the patient not have a biopsy? Check all that apply.

3%

Quite a bit

Changed frequency of scans Changed frequency of follow-up

No impact on screening or further care

37%

28%

74%

Very much

28%

Not offered 22%

14% Offered adjuvant therapy

Concern for spread

14%

Other 21%

“I completed the VISION survey in order to add my data. Ocular melanoma is a rare cancer so pooling all the data is vitally important to view the big picture of who this cancer effects, what treatments show promise and the challenges we all face. We are stronger together!” — VISION Participant in USA PATIENT VOICE

Unknown 7%

Side effects 2%

Cost 0%

Other 27%

2023 VISION Registry Data Report

18

Made with FlippingBook Ebook Creator